Showing 1 to 10 of 10 results
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Progress
40% Bias Score
Novo Nordisk's Fall from Grace in Obesity Drug Market
Novo Nordisk's market dominance in obesity medications has crumbled due to increased competition from Eli Lilly and compounding pharmacies offering cheaper alternatives, resulting in a 70% stock price drop and two downward revisions of its 2025 growth predictions.
Novo Nordisk's Fall from Grace in Obesity Drug Market
Novo Nordisk's market dominance in obesity medications has crumbled due to increased competition from Eli Lilly and compounding pharmacies offering cheaper alternatives, resulting in a 70% stock price drop and two downward revisions of its 2025 growth predictions.
Progress
60% Bias Score
Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback
Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...
Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback
Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...
Progress
36% Bias Score
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Progress
40% Bias Score
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Progress
48% Bias Score
Denmark's Economic Growth Forecast Cut in Half Amidst Novo Nordisk Slowdown
Denmark's 2025 economic growth forecast has been slashed from 3% to 1.4% due to weaker-than-expected performance by Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, resulting from increased competition, inventory buildup, and new US tariffs.
Denmark's Economic Growth Forecast Cut in Half Amidst Novo Nordisk Slowdown
Denmark's 2025 economic growth forecast has been slashed from 3% to 1.4% due to weaker-than-expected performance by Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, resulting from increased competition, inventory buildup, and new US tariffs.
Progress
20% Bias Score
Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition
Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.
Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition
Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.
Progress
40% Bias Score
CMS Raises Medicare Advantage Reimbursement Rate by 5.06%, Adding $25 Billion
CMS raised the 2026 Medicare Advantage reimbursement rate by 5.06%, adding $25 billion, reversing previous cuts that eliminated plans covering 1.5 million beneficiaries in 2025 and led to higher costs and fewer benefits; CMS also withdrew a proposal to expand coverage for obesity drugs.
CMS Raises Medicare Advantage Reimbursement Rate by 5.06%, Adding $25 Billion
CMS raised the 2026 Medicare Advantage reimbursement rate by 5.06%, adding $25 billion, reversing previous cuts that eliminated plans covering 1.5 million beneficiaries in 2025 and led to higher costs and fewer benefits; CMS also withdrew a proposal to expand coverage for obesity drugs.
Progress
44% Bias Score
Novo Nordisk Stock Plummets 40% on CagriSema Trial Results
Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...
Novo Nordisk Stock Plummets 40% on CagriSema Trial Results
Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...
Progress
40% Bias Score
El auge de fármacos contra la obesidad reduce las cirugías bariátricas en Estados Unidos
El uso de agonistas del receptor GLP-1 para tratar la obesidad aumentó un 123% en Estados Unidos entre 2022 y 2023, mientras que las cirugías bariátricas disminuyeron un 25%, planteando un cambio en las estrategias terapéuticas y la necesidad de evaluar la combinación de ambos tratamientos.
El auge de fármacos contra la obesidad reduce las cirugías bariátricas en Estados Unidos
El uso de agonistas del receptor GLP-1 para tratar la obesidad aumentó un 123% en Estados Unidos entre 2022 y 2023, mientras que las cirugías bariátricas disminuyeron un 25%, planteando un cambio en las estrategias terapéuticas y la necesidad de evaluar la combinación de ambos tratamientos.
Progress
40% Bias Score
Showing 1 to 10 of 10 results